MALVERN, Pa. -- Frontage Laboratories (http://www.frontagelab.com), a leading high quality provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry, announced today it has acquired a significant equity interest in Advanced Biomedical Research, Inc. (ABR) (http://www.abr-pharma.com), an international, full service CRO. With the completion of this initial phase acquisition, the combined resources of Frontage and ABR offer unparalleled formulation development, bioanalytical and GMP testing services, Phase I-II study performance in a state-of-the-art 72-bed clinical research facility